811810-67-0Relevant articles and documents
Modified benzoxazolone derivative as 18-kDa TSPO ligand
Kumari, Neelam,Chadha, Nidhi,Srivastava, Pooja,Mishra, Lokesh Chandra,Bhagat, Sunita,Mishra, Anil K.,Tiwari, Anjani K.
, p. 511 - 519 (2017/09/13)
We have synthesized six new congeners of acetamidobenzoxazolone for Translocator Protein [18 kDa, TSPO] imaging. The best in vitro binding affinity (10.8?±?1.2?nm) for TSPO was found for N-methyl-2-(5-(naphthalen-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)-N-phen
TRPV1 vanilloid receptor antagonists with a bicyclic portion
-
Page/Page column 22, (2011/11/01)
The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.
SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS
-
Page/Page column 72-73, (2008/06/13)
Compounds of formula (I); (wherein variables A1, A2. A3, A4, A5, A6, A7, B3 E1, E2, E3, E4, E5, G1, G2 and R.6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.